Financial Data and Key Metrics Changes - Quanterix reported revenue of $35.2 million for Q4 2024, an 11% increase year-over-year [10][28] - Non-GAAP gross margin improved to 57.7%, up 300 basis points from the previous year [11][31] - Cash usage declined by 31% to $4.4 million in Q4 2024 [11] Business Line Data and Key Metrics Changes - Accelerator lab revenue reached $8.6 million, a 22% increase driven by clinical trial testing services [29] - Consumable revenue remained flat at $17.4 million as customers transitioned to Advantage PLUS assays [29] - Instrument revenue decreased by 7% to $3.1 million but increased by 29% sequentially [30] Market Data and Key Metrics Changes - North America led revenue growth with a 17% increase, while Europe grew by 11% and Asia-Pacific declined by 6% for the full year [35] - The customer mix for the year was approximately 54% pharma and 46% academia [34] Company Strategy and Development Direction - The company aims to grow its leadership in neurology and expand into immunology and oncology markets through the Simoa ONE platform and the acquisition of Akoya Biosciences [15][20] - Quanterix plans to build a global diagnostic testing infrastructure for Alzheimer's disease, having added 12 partners to its network [17][18] - The company expects to achieve $40 million in operating synergies from the Akoya acquisition by 2026 [23][25] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the Accelerator business despite market volatility, citing a strong pipeline and diverse customer base [26][52] - The company anticipates a revenue range of $140 million to $146 million for 2025, reflecting a growth of 2% to 6% [40] - Management noted that 20% to 25% of annual revenues are tied to U.S. academic customers, which are expected to decline by 10% in 2025 [41] Other Important Information - The company ended Q4 2024 with $291.7 million in cash and equivalents [36] - Adjusted EBITDA was negative $23.6 million in 2024, compared to negative $19 million in 2023 [38] Q&A Session Summary Question: Impact of NIH academic government on revenue - Management acknowledged the pressure from NIH and indicated that the academic market is experiencing paralysis, affecting decision-making and spending [58][76] Question: Confidence in second half recovery - Management expressed confidence in the Accelerator business, citing a strong pipeline and expected larger projects to materialize in the second half of the year [52][75] Question: Details on validation phase with hospitals - Management confirmed that 10 hospitals are in the validation phase, with some actively in contract negotiations [54] Question: Concerns about the Akoya merger - Management emphasized the long-term value of the Akoya merger, focusing on recurring revenues and synergies [60][82] Question: Revenue guidance and academic market assumptions - Management indicated that the guidance incorporates expected declines in the academic market and potential upside if funding improves [77][88] Question: Simoa ONE launch impact - Management expects the Simoa ONE platform to launch at the end of 2025, expanding the addressable market in immunology and oncology [67][70] Question: Growth expectations outside the U.S. - Management anticipates low double-digit to high single-digit growth outside the U.S., aligned with overall expectations for 2024 [103]

以下文章来源于超越 J Curve ，作者超越J曲线 超越 J Curve . 作者丨投中研究院 来源丨超越 J Curve 核心发现 用数据延伸你的阅读 将投中网设为"星标⭐"，第一时间收获最新推送 本期带来2025年2月并购报告， 交易数量同比腰斩，电子信息行业领跑并购热潮。 第一部分 中企并购市场数据分析 并购市场宣布交易月度趋势 2025年2月，披露预案291笔并购交易，环比下降10.46%，同比下降70.61%；当中披露金额的有134笔， 交易总金额为165.17亿美元，环比上升36.91%，同比上升90.31%。虽然交易数量减少，但交易金额的增 2月，受春节及全球市场影响，中企并购市场交易数量呈现下降态势，但交易规模逆势增长。大额交易 量环比有所增加，反映出市场在调整过程中，大额优质项目依然受到关注 共计20支私募基金以并购的方式成功退出，回笼金额为2.04亿元 电子信息、医疗健康和传统制造行业的并购交易数量较为突出，广州交易规模位居榜首 长表明市场上仍存在大规模、高价值的并购项目。 图1-2024年2月-2025年2月中企并购市场宣布交易趋势 并购市场完成交易月度趋势 2025年2月，共计完成2 ...

Group 1 - The Trump administration is expected to maintain a rigorous stance on mergers and acquisitions (M&A), continuing the scrutiny established under the Biden administration [2][4] - The Department of Justice (DOJ) has already taken action by suing to block a $14 billion acquisition of Juniper Networks by Hewlett Packard Enterprise, citing concerns over reduced competition [3][4] - Strict guidelines from the Federal Trade Commission (FTC) and DOJ focus on preventing major deals that could lessen competition and reduce consumer options [5][6] Group 2 - Investment banks had anticipated a more favorable environment for M&A under the Trump administration, hoping for looser restrictions that could lead to increased deal activity and advisory revenue [7][8] - Despite the scrutiny on large tech deals, there may still be opportunities in other sectors, such as banking, where the Federal Deposit Insurance Corporation has rescinded a policy that could encourage large bank mergers [9] - Goldman Sachs has seen an 88% increase in stock price since November 2023, while Morgan Stanley and JPMorgan Chase are trading at elevated price to tangible book values compared to historical averages, prompting considerations for profit-taking [10]

Financial Data and Key Metrics Changes - Net income for Q4 2024 was $130 million, an increase of $34 million or 36% compared to Q4 2023 [6] - Diluted earnings per share rose to $1.37, up 34% from $1.02 in the same period last year [7] - Annualized return on average assets was 1.31% and average tangible common equity was 13.5% for Q4 2024 [8] - Net interest margin increased by 30 basis points to 3.05% compared to 2.75% in Q4 2023 [9] Business Line Data and Key Metrics Changes - Loans outstanding at Dec. 31, 2024, were $2.22 billion, a 4.6% increase from $2.12 billion at Dec. 31, 2023, primarily due to the merger with Lone Star Bank [10] - Deposits increased to $2.84 billion, up 4.4% from $2.72 billion at Dec. 31, 2023 [12] - Non-interest income for Q4 2024 was $39.8 million, compared to $36.6 million in Q4 2023 [20] Market Data and Key Metrics Changes - Non-performing assets totaled $81.54 million, or 37 basis points of loans, down from $89.92 million or 40 basis points at Sept. 30, 2024 [23] - The allowance for credit losses on loans was $3.89 million at Dec. 31, 2024 [15] Company Strategy and Development Direction - The company is interested in mergers and acquisitions, with indications that banks are more open to transactions under the new administration [15] - The Texas and Oklahoma economies are viewed positively, with Texas experiencing significant population growth [16] - The company aims to maintain a strong capital position to support growth opportunities without needing additional capital [17] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about organic loan growth in 2025, citing positive customer sentiment post-election [11] - The company expects net interest margin to continue expanding as assets reprice [17] - Management noted that the current economic environment is conducive to growth, with a favorable political climate in Texas and Oklahoma [16] Other Important Information - A stock repurchase program was announced, allowing for the acquisition of up to 5% of outstanding common stock over one year [9] - The efficiency ratio for Q4 2024 was 46.1%, an improvement from 55.6% in Q4 2023 [22] Q&A Session Summary Question: Update on NIM trajectory - Management expects NIM to be around 3.25% to 3.35% for 2025, with positive sentiment about the trajectory [33][34] Question: Loan growth sentiment - Management noted positive customer sentiment and anticipates low to mid-single-digit loan growth, with improvements expected in the Texas market [41][42] Question: Securities portfolio yield outlook - Management expects the yield on the securities portfolio to improve as they reinvest in higher-yielding securities [58] Question: Provision for credit losses - Management indicated that the current reserve levels are sufficient unless there are significant changes in the credit outlook [66][67] Question: Deposit growth outlook - Management anticipates a return to a more normalized deposit growth rate of 2% to 2.5% for the year [84]

2025第一波VC募资。 作者 I 刘博 报道 I 投资界PEdaily 投资界获悉，元禾璞华产业并购基金已完成首关，首关规模超12亿元，预计今年第二季度完成基金终关，终关规模不低于20亿元。此 次LP阵容中，基石投资人为苏州元禾控股股份有限公司、安徽省高新技术产业投资有限公司，华大九天、晶丰明源、安凯微等多家上 市公司、金融机构以及多地政府引导基金同样位列其中。 坚定信仰中国半导体产业的长期成长，悄然成为元禾璞华的底色。十年浮沉，这支队伍正向着远方再度出发。 并购基金打头阵 今年第一波超级募资 并购基金来得恰逢其时。 放眼国内，随着去年9月"并购六条"发布，一笔笔重磅并购交易目不暇接。然而并购市场热闹景象背后，交易多由上市公司发起，参与 者中主要投向半导体的并购基金鲜少看见。 与此同时，元禾璞华新一期PE基金和新一期VC基金，分别与上海、北京、江苏等多地政府引导母基金合作设立，同样将在今年一季度 完成首关，基金规模均在10亿- 2 0亿元。募资数十亿，这样一幕放在"募资难"的背景下显得弥足珍贵。 LP总是用脚投票。2024年是元禾璞华成立的十周年，迄今基金管理规模过百亿，累计投资约20 0家半导体和硬科技企 ...

文/梧桐数据中心 2024年全年，A股并购重组项目上会审核企业共计15家，沪主板4家，科创板3家，深主板3家，创业板5家。其中，14家企业审核通过，1家被否。 本文统计了2024年审核通过的14单并购重组业务，中介机构业绩排名情况如下： 一、独立财务顾问业绩排名 2024年全年，共有9家独立财务顾问机构承办了这14单并购重组过会项目的保荐业务。 中信证券排名第一，业务单数为5单； 华泰联合证券排名第二，业务单数为2单； 华安证券、东方证券、东吴证券、国泰君安证券、华创证券、浙商证券、中信建投证券各1单。 | T | TIDEJ | | | --- | --- | --- | | 2 | 华泰联合 | 2 | | 3 | 华安证券 | 1 | | 3 - | 东方证券 | 1 | | 3 | 东吴证券 | III F | | 3 | 国泰君安 | 1 | | 3 | 华创证券 | 1 | | 3 | 浙商证券 | 1 | | 3 | 中信建投 | 1 | | | 合计 | 14 | 二、法律顾问业绩排名 北京通商、北京中伦、广东华商、国浩（上海）、国浩（长沙）、上海锦天城各1单。 2024年全年，共有10家律师 ...

编辑丨程曼褀 我们获悉，阿里巴巴集团战投原负责人胡晓近日离开阿里，加入了刘晓丹创立的并购基金晨壹基金。今年 3 月，阿里巴巴集团原董事会主席兼 CEO 张勇（花名逍遥子）已宣布加入晨壹，任管理合伙人。 胡晓自 2017 年加入阿里，历任阿里投资战略部总监、董事总经理。在离开前，她是阿里集团战投的负责 人，向阿里 CFO 徐宏汇报，在阿里期间，胡晓曾任圆通速递、红星美凯龙的非独立董事，小鹏汽车的非 执行董事。 据了解，今年春节前后，胡晓推动了阿里集团战投部对大模型独角兽月之暗面 8 亿美元的投资。 加入阿里前的 2008 年-2017 年，胡晓曾历任花旗环球（亚洲）经理、副总裁，和美林证券（亚太）副总裁、 董事。 胡晓自 2018 年起担任华泰证券的非执行董事，晨壹创始合伙人刘晓丹则在 2012 - 2019 年任华泰联合（华泰 联合为华泰证券控股子公司）总裁、董事长。 阿里集团前 CEO 张勇今年 3 月宣布加入晨壹基金，该基金由 "并购女皇" 刘晓丹创立。 文丨王与桐 刘晓丹曾主导华泰证券收购美国统包资产管理平台 AssetMark，帮助拓展华泰国际业务；她操作的知名案例 还有 360 私有化、迈瑞医疗 I ...

As filed with the Securities and Exchange Commission on February 12, 2024. Registration No. 333-272908 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549F AMENDMENT NO. 15 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ___________________________ SEQLL INC. (Exact name of registrant as specified in its charter) ___________________________ | Delaware | 3826 | 46-5319744 | | --- | --- | --- | | (State or other jurisdiction of | (Primary Standard Industrial | (I.R.S. E ...

As filed with the Securities and Exchange Commission on October 27, 2023. Registration No. 333-272908 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549F AMENDMENT NO. 6 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ___________________________ SEQLL INC. (Exact name of registrant as specified in its charter) ___________________________ | Delaware | 3826 | 46-5319744 | | --- | --- | --- | | (State or other jurisdiction of | (Primary Standard Industrial | (I.R.S. Emp ...

As filed with the Securities and Exchange Commission on September 14, 2023. Registration No. 333-272908 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549F AMENDMENT NO. 3 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ___________________________ SEQLL INC. (Exact name of registrant as specified in its charter) ___________________________ | Delaware | 3826 | 46-5319744 | | --- | --- | --- | | (State or other jurisdiction of | (Primary Standard Industrial | (I.R.S. E ...